SMS PHARMACEUTICALS LTD.
SMSPHARMA · General/Diversified · NSE
₹417
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SMSPHARMA yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
20%
ROE
10.8%
Debt/Equity
0.49
WACC
11.1%
Market Cap
₹3,910 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.2%
Return on capital employed
EV / EBITDA
21.7×
Enterprise multiple
Debt / EBITDA
2.1×
Leverage vs earnings
Interest Coverage
6.3×
EBIT covers interest
Current Ratio
1.71×
Short-term liquidity
Asset Turnover
0.71×
Revenue per ₹ of assets
Revenue CAGR (3Y)
19.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
SMSPHARMA · last 8 annual periods
ROE
10.8%
ROCE
15.2%
Operating Margin
—
Debt / Equity
0.49×
PE
87.7×
EV / EBITDA
11.5×
Historical Financials
SMSPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹515 Cr | ₹520 Cr | ₹706 Cr | ₹783 Cr | ₹887 Cr | +14.6% |
| EBITDA | ₹119 Cr | ₹58.5 Cr | ₹120 Cr | ₹145 Cr | ₹180 Cr | +10.9% |
| EBIT | ₹87.4 Cr | ₹27.3 Cr | ₹89.6 Cr | — | — | +0.6% |
| PAT | ₹62.2 Cr | ₹-7.1 Cr | ₹49.8 Cr | ₹69.1 Cr | ₹102 Cr | +13.2% |
| EPS (diluted) | ₹7.35 | ₹0.00 | ₹5.89 | — | — | -5.4% |
| CFO | ₹45.1 Cr | ₹22.4 Cr | ₹50.1 Cr | ₹81.7 Cr | ₹59.2 Cr | +7.1% |
| CapEx | ₹-27.2 Cr | ₹-29.9 Cr | ₹-52.2 Cr | ₹-123 Cr | ₹-131 Cr | — |
| FCF | ₹17.8 Cr | ₹-7.5 Cr | ₹-2.0 Cr | ₹-41.7 Cr | ₹-71.3 Cr | — |
| Total Assets | ₹860 Cr | ₹880 Cr | ₹1034 Cr | ₹1153 Cr | ₹1362 Cr | +12.2% |
| Total Debt | ₹263 Cr | ₹254 Cr | ₹281 Cr | ₹311 Cr | ₹365 Cr | +8.5% |
| Shareholders' Equity | ₹470 Cr | ₹461 Cr | ₹536 Cr | ₹640 Cr | ₹786 Cr | +13.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SMSPHARMA vs 4 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SENORES SENORES | — | — | Pending | 7.2% | — |
SAIPARENT SAIPARENT | — | — | Pending | 15.9% | — |
 NGLFINE NGLFINE | — | — | Pending | 14.6% | — |
 TTKHLTCARE TTKHLTCARE | — | — | Pending | 7.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1.70/sh
Last payout
2025-09-22
₹0.40
Peak payout
₹0.40
Trailing yield
0.10%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of SMSPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SMSPHARMA →
Compare
Head-to-head with peers
Compare SMSPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SMSPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.